Inozyme Pharma Inc (NAS:INZY)
$ 5.77 0.31 (5.68%) Market Cap: 356.90 Mil Enterprise Value: 216.98 Mil PE Ratio: 0 PB Ratio: 3.01 GF Score: 40/100

Inozyme Pharma Inc at Piper Sandler Healthcare Conference Transcript

Nov 29, 2022 / 05:30PM GMT
Release Date Price: $1.48 (+1.37%)
Unidentified Participant

Okay. Let's go ahead and get started with our next session. Thanks everybody for joining us. This is our 34th Annual Piper Sandler Healthcare Conference. Pleased to have with us our next presenter, which is Inozyme Pharma. The CEO, Axel Bolte is with me, next to me. I go through this every session, but just for everybody's benefit, this is a fireside chat, so by definition, very informal. So if anybody has any questions, please raise your hand. I'll make sure it gets asked and answered.

Axel, maybe before we launch into my questions, just for folks who might not necessarily understand the story or have familiarity with it, walk us through maybe sort of the elevator pitch, if you will, of Inozyme. And then I'll jump into my peppering you with questions.

Axel Bolte
Inozyme Pharma, Inc. - Co-founder, President & CEO

That's great. Thank you, [Chris], and thanks a lot for inviting us. And we're obviously delighted to be here at the conference today. So Inozyme is a rare disease company. We're focused on these orders of mineralization.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot